glofitamab + gemcitabine + oxaliplatin

Glofitamab + gemcitabine + oxaliplatin is an investigational combination regimen used in clinical trials for **relapsed or refractory diffuse large B-cell lymphoma (DLBCL)**, particularly in patients ineligible for autologous stem cell transplantation. Glofitamab is a bispecific monoclonal antibody targeting CD20 on B cells and CD3 on T cells, leading to T-cell mediated cytotoxicity of malignant B cells. Gemcitabine is a nucleoside analog that inhibits DNA synthesis, and oxaliplatin is a platinum-based alkylating agent causing DNA crosslinking and apoptosis. This regimen, often called Glofit-GemOx, is administered intravenously in 21-day cycles (gemcitabine 1000 mg/m², oxaliplatin 100 mg/m²) with step-up dosing of glofitamab, preceded by obinutuzumab pretreatment to reduce cytokine release syndrome risk. Phase 3 data (STARGLO trial) shows improved overall survival compared to rituximab-GemOx and manageable toxicity. The regimen is not yet approved for clinical use and remains under investigation.

Other names

Glofit-GemOxGlofitamab-GemOxGemOx